Unum racks up yet an­oth­er FDA hold as it twists its way through a re­struc­tur­ing, look­ing for a fresh start with a pre­clin­i­cal drug

The drum­beat of bad news at Unum Ther­a­peu­tics just won’t stop.

In a fil­ing with the SEC to­day, the trou­bled biotech re­port­ed that its ex­per­i­men­tal ther­a­py AC­TR707 — used in com­bi­na­tion with rit­ux­imab in pa­tients with CD20+ B cell non-Hodgkin lym­phoma — may have been re­spon­si­ble for a pos­si­ble new ma­lig­nan­cy. The FDA slapped a par­tial hold on the study March 4 while the agency and the biotech ex­plore what hap­pened to trig­ger the Grade 3 SAE.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.